About
14
Publications
3,087
Reads
How we measure 'reads'
A 'read' is counted each time someone views a publication summary (such as the title, abstract, and list of authors), clicks on a figure, or views or downloads the full-text. Learn more
171
Citations
Introduction
Data scientist and cancer researcher experienced with a range of data types, including next-generation sequencing and large-scale clinical data. Skilled in data acquisition, cleaning and transformation, exploratory analyses, applying statistical and predictive machine learning models, and advanced graphical visualisation techniques. Competent in developing and deploying scalable, automated high-performance computing workflows, dashboard and web app development, and reporting in various formats.
Current institution
Additional affiliations
June 2022 - May 2023
Position
- Cancer Bioinformatician
Description
- Creating a mutational map of the 100,000 Genomes Project bladder cancer and ovarian cancer cohorts, contributing bioinformatics capability to the GUSTO phase II clinical study, and supporting several smaller clinical and basic science projects.
September 2017 - August 2019
Position
- Postdoctoral Research Associate
Description
- Integrating novel models of mitotic quiescence in breast cancer in vitro and in vivo with NGS and bioinformatic analyses to elucidate molecular mechanisms of resistance to standard of care therapies.
September 2019 - June 2022
Position
- Postdoctoral Cancer Bioinformatician
Description
- Integrating novel models of mitotic quiescence in breast cancer with NGS and bioinformatic analyses to elucidate molecular mechanisms of metastatic dormancy.
Education
September 2014 - August 2017
Publications
Publications (14)
Objective
We report NHS England data for patients with bladder cancer (BC), upper tract urothelial cancer (UTUC: renal pelvic and ureteric), and urethral cancers from 2013 to 2019.
Materials and Methods
Hospital episode statistics, waiting times, and cancer registrations were extracted from NHS Digital.
Results
Registrations included 128 823 indi...
Excessive production of Transforming Growth Factor β (TGFβ) is commonly associated with dominant and recessive forms of OI. Previous reports have indicated that administration of TGFβ-targeted antibodies maybe of potential therapeutic benefit to OI patients. However, direct targeting of TGFβ is likely to cause multiple adverse effects including sim...
TPS4621
Background: Muscle invasive bladder cancer (MIBC) is an aggressive disease with poor survival rates that are not improving. Curative treatment includes systemic neoadjuvant chemotherapy prior to radical cystectomy and adjuvant immunotherapy. However, many patients do not respond to chemotherapy or immunotherapy. Histologically similar MIBCs...
The GUSTO clinical trial (Gene expression subtypes of Urothelial carcinoma: Stratified Treatment and Oncological outcomes) uses molecular subtypes to guide neoadjuvant therapies in participants with muscle-invasive bladder cancer (MIBC). Before commencing the GUSTO trial, we needed to determine the reliability of a commercial subtyping platform (De...
Background: Neoadjuvant chemotherapy (NAC) prior to radical cystectomy is standard of care for muscle invasive bladder cancer (MIBC). Currently this approach is offered to all eligible patients however recent studies that classified MIBC by gene expression signatures indicate that the response to NAC may vary by subtype. Gene expression subtypes of...
Metastatic recurrence, the major cause of breast cancer mortality, is driven by reactivation of dormant disseminated tumour cells that are defined by mitotic quiescence and chemoresistance. The molecular mechanisms underpinning mitotic quiescence in cancer are poorly understood, severely limiting the development of novel therapies for removal of re...
Breast cancer bone metastasis is currently incurable, ~75% of patients with late-stage breast cancer develop disease recurrence in bone and available treatments are only palliative. We have previously shown that production of the pro-inflammatory cytokine interleukin-1B (IL-1B) by breast cancer cells drives bone metastasis in patients and in precli...
The bone marrow is comprised of a diverse array of cell types, including those of mesenchymal origin (e.g., osteoblasts, osteocytes, and adipocytes), those of hematopoietic origin (e.g., immune cells and osteoclasts), endothelial cells and nerve cells. It has long been appreciated that the niche microenvironments formed by these cells are not only...
Bone is a common site of metastasis in many cancers including breast, prostate and multiple myeloma. The dissemination of tumor cells into bone is thought to be an early event, often occurring before clinical detection of the primary tumor. Despite this, overt metastases do not usually develop until many years later. When tumor cells arrive in the...
Metastatic recurrence in breast cancer is a major cause of mortality and often occurs many years after removal of the primary tumour. This process is driven by the reactivation of disseminated tumour cells that are characterised by mitotic quiescence and chemotherapeutic resistance. The ability to reliably isolate and characterise this cancer cell...
Components of the mitochondrial electron transport chain have recently gained much interest as potential therapeutic targets. Since mitochondria are essential for the supply of energy that is required for both angiogenic and tumourigenic activity, targeting the mitochondria represents a promising potential therapeutic approach for treating cancer....
Novel therapeutic strategies to eliminate chemo-resistant tumour cells responsible for the development of secondary lesions are essential in order to prevent breast cancer relapse. We have developed an model system enabling isolation of a putative metastasis-initiating breast cancer cell sub-population with a mitotically quiescent, drug-resistant p...
Metastasis to the bone is most frequently observed in advanced cases of breast and prostate cancer. The latent development of overt metastatic lesions is associated with debilitating skeletal morbidity and eventual patient mortality. Secondary tumours in bone are derived from disseminated tumour cells (DTCs) that enter into a state of cellular dorm...
